Cardio3 appoints Atta Behfar
This article was originally published in Clinica
Atta Behfar has joined Belgian biotech company Cardio3 as director for advanced research. Dr Behfar was one of the scientists involved in developing the firm's C-Cure stem cell-based therapy, and is a researcher at the Mayo Clinic in Rochester, Minnesota. In his new role, he will spend a year on assignment from the clinic to "develop and strengthen" Cardio3's research pipeline. He won the young investigator award at this year's American College of Cardiology meeting, held in March in Atlanta, Georgia, for his work on C-Cure. Mont-Saint-Guibert-based Cardio3 recently presented promising early data from the first human trial of the product, which is designed to heal damaged heart tissue by reprogramming the patient's own stem cells so that they become heart cells (www.clinica.co.uk, 30 June 2010).